Next Generation Sequencing and Genotyping Core Facility. The goal of the Next Gen Sequencing component is to make """"""""next generation"""""""" sequencing and related services widely available to UNC LCCC members at cost-effective prices. Services include: whole genome shotgun sequencing of human and model organisms, chromatin-IP sample sequencing, measuring RNA expression with both digital gene expression and RNA-seq, SNP typing, and polymorphism screens. The component adds value to the cancer center by putting complex and expensive DNA/RNA sequencing technology within easy reach of UNC LCCC members. Strongly integrated genomics and bioinformatics groups interact with the user to ensure robust data that is archived appropriately for future use. This component is key in UNC LCCC's participation in The Cancer Genome Atlas project and serving LCCC needs. Future plans Include expanding staff and equipment so that a full array of Next Gen sequencing and services may be provided in a timely manner, as well as the acquisition of the next generation of technology. The goal of the DNA Sequencing component is to produce high quality sequencing and genotyping data rapidly and at a reasonable cost for UNC-CH researchers using state-of-the-art technologies as well as provide technical support to enhance the value of results produced. Services include DNA sequencing and microsatellite genotyping. The component adds value to the cancer center by producing high-quality data at a competitive price while providing the benefits of a local resource to assist in: scientific strategies, sample preparation, sequencing through difficult regions, and assistance in data interpretation. This component has a wide user base with over 220 different laboratories as users in 2009. Future plans include continued use of existing equipment, reduction of chemistry costs, and evaluation of future sequencing technology options such as long read single molecule sequencing technologies. The goal of the High Throughput Genotyping component is to produce high-quality genotyping data rapidly and at a reasonable cost for researchers using state-of-the-art technologies. Services include SNP genotyping, copy number variation and DNA methylation profiling analysis. New technologies and/or applications are being explored to increase the core's competitive edge and to allow for Genome Wide Association Study on rare variants. These core components are used by multiple members and in each core, peer reviewed member used exceeds 70%. The proposed budget of $241,797 is less than 5% of the core's operating cost. The budget provides salary stability for vital core staff who work with members to adopt these novel technologies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016086-38
Application #
8594163
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
38
Fiscal Year
2014
Total Cost
$243,309
Indirect Cost
$66,183
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Brosnan, Evelyn M; Anders, Carey K (2018) Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies. Ann Transl Med 6:163
Valle, Carmina G; Queen, Tara L; Martin, Barbara A et al. (2018) Optimizing Tailored Communications for Health Risk Assessment: A Randomized Factorial Experiment of the Effects of Expectancy Priming, Autonomy Support, and Exemplification. J Med Internet Res 20:e63
Sun, Junjiang; Shao, Wenwei; Chen, Xiaojing et al. (2018) An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs. Mol Ther Methods Clin Dev 10:257-267
Wilczewski, Caralynn M; Hepperla, Austin J; Shimbo, Takashi et al. (2018) CHD4 and the NuRD complex directly control cardiac sarcomere formation. Proc Natl Acad Sci U S A 115:6727-6732
Waters, Andrew M; Der, Channing J (2018) KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harb Perspect Med 8:
Cai, Ling; Tsai, Yi-Hsuan; Wang, Ping et al. (2018) ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. Mol Cell 72:341-354.e6
Moschos, Stergios J; Sullivan, Ryan J; Hwu, Wen-Jen et al. (2018) Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. JCI Insight 3:
Mirlekar, Bhalchandra; Michaud, Daniel; Searcy, Ryan et al. (2018) IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer. Cancer Immunol Res 6:1014-1024
Buist, Diana S M; Abraham, Linn; Lee, Christoph I et al. (2018) Breast Biopsy Intensity and Findings Following Breast Cancer Screening in Women With and Without a Personal History of Breast Cancer. JAMA Intern Med 178:458-468
Zhang, Jing; Wu, Tao; Simon, Jeremy et al. (2018) VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. Science 361:290-295

Showing the most recent 10 out of 1525 publications